Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-04

Clinical Trial Update: Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 efficacy trial of EVO301 in moderate-to-severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EVO301

Snippet

Sponsor: Evommune, Inc. | Conditions: Atopic Dermatitis (AD), Eczema | Phase 2 | Status: COMPLETED